Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Portfolio Pulse from Vandana Singh
Boston Scientific Corporation (NYSE:BSX) reported strong Q2 earnings, with revenues of $4.12 billion and an adjusted EPS of $0.62, both beating consensus estimates. The company raised its 2024 guidance, forecasting net sales growth of 13.5%-14.5% and adjusted EPS of $2.38-$2.42. Despite the positive results, BSX stock was trading lower by 1.95%.
July 24, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific reported strong Q2 earnings, beating revenue and EPS estimates. The company raised its 2024 guidance, forecasting higher net sales growth and adjusted EPS. Despite the positive results, BSX stock was trading lower by 1.95%.
Boston Scientific's strong Q2 performance and raised guidance for 2024 indicate positive future prospects. However, the stock trading lower by 1.95% suggests a potential short-term market correction or profit-taking. Overall, the long-term outlook remains positive.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100